Tirelizumab Clinical Trials

2 actively recruiting trials

No change since May 2026

Also known as: anti-PD-1 monoclonal antibody

Pipeline

Phase 2: 2

Top Sponsors

Ruijin Hospital1
Huihua Xiong1

Indications

Cancer2
TNBC - Triple-Negative Breast Cancer1
Esophageal Squamous Cell Carcinoma1
Breast Cancer1

Other2 trials

Optimization of Treatment Strategy for Unresectable cN3 Esophageal Squamous Cell Carcinoma

Phase 2

The Efficacy and Safety of Utidelone Plus Tirelizumab and Bevacizumab for Advanced or Metastatic Triple-negative Breast Cancer (UTILIZABLE) ：Single-arm, Prospective, Open Clinical Study

Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.